Project Grant HT94252410739

The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $793,324 Project Grant to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors against CYP8B1, a novel therapeutic target for treating hepatocellular carcinoma (HCC), including metabolic dysfunction associated HCC. The research aims to address the critical unmet need for innovative pharmacological therapies with desirable safety profiles and durable treatment effects for...

This $946,540 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program. Health Research-Roswell Park Cancer Institute Division will target HNF1A-mediated therapeutic resistance in pancreatic ductal adenocarcinoma. The researchers will characterize regulation of the HNF1A gene by the BRD4 protein and establish bromodomain inhibitors as a means to overcome HNF1A-mediated resistance to KRAS...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...

Federal Project Grant Award Summary Hepatx Corporation received a $175,964 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on May 13, 2025, with completion targeted for April 30, 2027. The company will develop and validate a proteomic blood test to monitor the success of transplanted hepatocytes in human patients. Using mass spectrometry methods to...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...

This Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute provides $582,100 to East Carolina University to support research on the role of mitochondrial complex I deficiency in colorectal cancer (CRC) tumor growth and progression. The research aims to elucidate how accumulated mitochondrial DNA mutations that disrupt complex I activity can paradoxically support CRC tumorigenesis, despite the general requirement for...

Riboscience LLC received a $306,739 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 12, 2025, with completion targeted for August 31, 2026. The award supports the development and evaluation of second-generation ENPP1 (ectonucleotide pyrophosphatase-phosphodiesterase 1) inhibitors for treating hepatocellular carcinoma (HCC). The research aims to identify the most effective ENPP1 inhibitors in HCC models to improve...

The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...

Grant Award Summary The Beckman Research Institute of the City of Hope received a $847,746 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the five-year period commencing September 1, 2025 through August 31, 2030. The research project, titled "Role of UPR Transducer XBP1 in Pancreatic Beta Cell Survival and Function Under Metabolic Stress,"...

Federal Grant Award Summary Baylor College of Medicine received a $626,429 Project Grant award effective July 1, 2025, through May 31, 2030, from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant funds research investigating the role of Carbohydrate Responsive Element Binding Protein (ChREBP), a transcription factor implicated in metabolic-associated steatohepatitis,...